Dr Kris Jeremy

Dr Kris Jeremy

Deputy Head of School

School of Biomedical Sciences (Faculty of Health)



Deputy Head of School, School of Biomedical Sciences 
Associate Professor of Biochemistry (Education)
Programme Lead - BSc (Hons) Biomedical Science (August 2015 - May 2021)
Blood pathway lead - HCS LS/BSc (Hons) Applied Biomedical Science 
Lecturer in Biomedical Science (Biochemistry) (August 2014 - August 2021)


Royal Air Force
IdentiGEN UK
BSc (Hons) Biochemistry
PhD Biomedical Science
Postgraduate Certificate in Teaching and Learning in Higher Education (PGCHE) 
PgDIP CMI Strategic Management and Leadership

Professional membership

Chartered Manager (CMgr)Chartered Biologist (CBiol)
Fellow of the Higher Education Academy (FHEA)
Fellow of the Institute of Biomedical Science (FIBMS)
Fellow of the Royal Society of Biology (FRSB)

Roles on external bodies

Education Officer - Institute of Biomedical Science (South Western Region)


Teaching interests

Module lead
FMD001 Molecules to Cells
BHCS3004 Specialist Biochemistry and Screening
FMD001 Molecules to Cells
BHCS1001 Biomedical Investigation and Experimentation
BHCS1002 Human Anatomy and Physiology: Cells to Systems
BHCS1003 Human Metabolism
DIET403 Nutritional Biochemistry
BHCS1005 Human Disease
BHCS1011 Study skills and personal development
BHCS2001 Biology of Disease
BHCS2002 Evidence-Based Practice in Biomedical Science
BHCS2005 Clinical Haematology and Biochemistry
BHCS2027 Placements and Employability
BHCS2020 Human Metabolism
DIET509 Diet, Metabolism and Health
BHCS2025 Nutritional Science 2
BHCS3001 Personal Research Project
BHCS3004 Specialist Biochemistry and Screening
BHCS3024 Diet, Exercise and Chronic Disease
BHCS3031 Personal development and employability
BIOM5002 Contemporary Applications of Cell Biology
BIOM5006 Research Project
BHCS5009 Cancer Biology and Therapeutics
BHCS5010 Contemporary Applications in Cancer Biology and Therapeutics
HNUT702 Applied Nutrition
Programme Lead
BSc (Hons) Biomedical Science (2015-2021)

Staff serving as external examiners

Bangor University - External examiner - BSc (Hons) Biomedical Science (2016 - 2020)
Cardiff Metropolitan University - External validation - BSc (Hons) Biomedical Science top-up - ICBT, Sri Lanka (2017)
UWE, Bristol - Programme Enhancement Review - External Panel Member - MSci Biological Sciences and BSc (Hons) Biological Sciences (2019)
Cardiff Metropolitan University - External examiner - BSc (Hons) Biomedical Science - (2021 - 2025)
ICBT, Sri Lanka - External Examiner - BSc (Hons) Biomedical Science top-up - (2021 - 2025) Cardiff Metropolitan University partnership
Dimensions, Singapore - External Examiner BSc (Hons) Biomedical Science top-up (2021 - 2025) Cardiff Metropolitan University partnership
Coleg Gwent, Newport, South Wales - External Academic Advisor - FdSc Biomedical Science (2024) Cardiff Metropolitan University partnership
New York College, Athens and Thessaloniki, Greece - External Academic Advisor - BSc (Hons) Biomedical Science (2024) University of Bolton partnership


Research interests

CD47 signalling in erythrocytes and AML cell lines
CD47 is a five transmembrane cell surface protein of the immunoglobulin (Ig) superfamily, which is heavily glycosylated and expressed by virtually all cells in the body. Ligation of CD47 with a monoclonal antibody (BRIC 126) and a synthetic peptide (4N1K) based on the C terminal binding domain of Thromobospondin-1 (TSP-1) leads to phosphatidylserine (PS) exposure and cell death in erythrocytes. Recent research has shown that CD47 is upregulated on solid tumours and is overexpressed on acute myeloid leukaemia (AML) cell lines. Overexpression of CD47 indicates poor prognosis in AML hence blockade of CD47 has improved cancer therapy. CD47 is also prognostic for breast cancer. 
Recent research has shown measurable amounts of PS exposure and cell death in several AML cell lines in response to BRIC126. It is hoped that research into this pathway will help to elucidate the underlying molecular mechanisms responsible for CD47 mediated phosphatidylserine exposure in AML cell lines. Several targets within this proposed pathway have already been identified for further study.

Grants & contracts

External grants: 
Co-investigator: Northcott Devon Medical Foundation: “Understanding the role of CD47 in colorectal cancer and the use of anti-CD47 monoclonal antibodies for potential cancer immunotherapy” - Awarded December 2019.


Jeremy, K. P., Plummer, Z. E., Head, D. J., Madgett, T. E., Sanders, K. L., Wallington, A., Storry, J. R., Gilsanz, F., Delaunay, J. & Avent, N. D. (2009) 4.1R-deficient human red blood cells have altered phosphatidylserine exposure pathways and are deficient in CD44 and CD47 glycoproteins. Haematologica, 94, 1354-61. 

Jeremy K, Delaunay J, Gilsanz F, Avent N Opposing effects of protein kinase A and C causes differential phosphatidylserine exposure in a CD47 receptor mediated erythrocyte apoptotic pathway (2008) Haematologica 93, S1:188 

Jeremy K, Plummer Z, Head D, Delaunay J, Gilsanz F, Avent N Proteomic and Biochemical Profiling of 4.1R deficient red blood cells (2007) Haematologica; 92, S1:342-343



Reports & invited lectures

25th British Blood Transfusion Society Annual Scientific Meeting, Glasgow SECC, Glasgow, September 13th-15th 2007 - Special Interest Group